Vical sees Progress on RapidResponse DNA Vaccine Platform

21 June 2009 (Last Updated June 21st, 2009 18:30)

Vical has received further funding to proceed with the development of its RapidResponse platform, designed to allow rapid and large-scale production of DNA vaccines with low capital requirements. The RapidResponse system will allow for the extremely rapid and large-scale production of D

Vical has received further funding to proceed with the development of its RapidResponse platform, designed to allow rapid and large-scale production of DNA vaccines with low capital requirements.

The RapidResponse system will allow for the extremely rapid and large-scale production of DNA vaccines, including those that affect large populations such as the H1N1 (swine flu) or H5N1 pandemic influenza or severe acute respiratory syndrome.

The third year of grant funding was awarded by the National Institute of Allergy and Infectious Diseases.

The company has completed significant second-year milestones under a three-year, $6m grant awarded in 2007, and is now advancing with the development of a DNA vaccine manufacturing process, to produce several million doses of vaccines in a matter of days.

The RapidResponse DNA vaccine manufacturing platform is intended to reduce the time required to develop, manufacture and deploy vaccines against emerging diseases during the early stages of an infectious outbreak.